Therapeutic Response

EGFR p.T790M status confers therapeutic sensitivity to Osimertinib in patients with Non-Small Cell Lung Cancer.

Statements

Source and description
Tagrisso (osimertinib) [product monograph]. HC. Health Canada approved osimertinib for the treatment of patients with locally advanced or metastatic EGFR T790M mutation-positive NSCLC whose disease has progressed on or after EGFR tyrosine kinase inhibitor (TKI) therapy.
Tagrisso (osimertinib) [package insert]. FDA. The U.S. Food and Drug Administration granted approval to osimertinib for the treatment of adult patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC), as detected by an FDA-approved test, whose disease has progressed on or after EGFR TKI therapy.